J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As we mark the 40th edi­tion of this Sat­ur­day re­cap, I’d like to spend a mo­ment mar­veling at just how much End­points News has grown in the past year. We used to just have two dai­ly re­ports. But we now send out week­ly email newslet­ters ded­i­cat­ed to phar­ma mar­ket­ing (End­points Mar­ket­ingRx), reg­u­la­to­ry news (End­points FDA+) and man­u­fac­tur­ing (End­points Man­u­fac­tur­ing). Want to get them in your in­box? You can cus­tomize your list of sub­scrip­tions in the read­er pro­file.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.